These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36413539)

  • 41. Artificial pancreas: an emerging approach to treat Type 1 diabetes.
    Kumareswaran K; Evans ML; Hovorka R
    Expert Rev Med Devices; 2009 Jul; 6(4):401-10. PubMed ID: 19572795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Customization of home closed-loop insulin delivery in adult patients with type 1 diabetes, assisted with structured remote monitoring: the pilot WP7 Diabeloop study.
    Benhamou PY; Huneker E; Franc S; Doron M; Charpentier G;
    Acta Diabetol; 2018 Jun; 55(6):549-556. PubMed ID: 29520615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Realizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes.
    Lal RA; Ekhlaspour L; Hood K; Buckingham B
    Endocr Rev; 2019 Dec; 40(6):1521-1546. PubMed ID: 31276160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Internal model control based module for the elimination of meal and exercise announcements in hybrid artificial pancreas systems.
    Sala-Mira I; Garcia P; Díez JL; Bondia J
    Comput Methods Programs Biomed; 2022 Nov; 226():107061. PubMed ID: 36116400
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Progress of artificial pancreas devices towards clinical use: the first outpatient studies.
    Russell SJ
    Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):106-11. PubMed ID: 25692927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Do-It-Yourself (DIY) Artificial Pancreas Systems for Type 1 Diabetes: Perspectives of Two Adult Users, Parent of a User and Healthcare Professionals.
    Ahmed SH; Ewins DL; Bridges J; Timmis A; Payne N; Mooney C; MacGregor C
    Adv Ther; 2020 Sep; 37(9):3929-3941. PubMed ID: 32696329
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of microdialysis-based continuous glucose monitoring to drive real-time semi-closed-loop insulin infusion.
    Freckmann G; Jendrike N; Pleus S; Buck H; Bousamra S; Galley P; Thukral A; Wagner R; Weinert S; Haug C
    J Diabetes Sci Technol; 2014 Nov; 8(6):1074-80. PubMed ID: 25205589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Closed-loop insulin delivery: from bench to clinical practice.
    Hovorka R
    Nat Rev Endocrinol; 2011 Feb; 7(7):385-95. PubMed ID: 21343892
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes.
    Tauschmann M; Hovorka R
    Expert Opin Drug Deliv; 2017 Dec; 14(12):1367-1377. PubMed ID: 28819992
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Automated Insulin Delivery Systems as a Treatment for Type 2 Diabetes Mellitus: A Review.
    Karol AB; O'Malley G; Fallurin R; Levy CJ
    Endocr Pract; 2023 Mar; 29(3):214-220. PubMed ID: 36241017
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glucose-responsive insulin delivery for type 1 diabetes: The artificial pancreas story.
    Bally L; Thabit H; Hovorka R
    Int J Pharm; 2018 Jun; 544(2):309-318. PubMed ID: 29258910
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Feasibility study of automated overnight closed-loop glucose control under MD-logic artificial pancreas in patients with type 1 diabetes: the DREAM Project.
    Nimri R; Atlas E; Ajzensztejn M; Miller S; Oron T; Phillip M
    Diabetes Technol Ther; 2012 Aug; 14(8):728-35. PubMed ID: 22853723
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Artificial pancreas: where are we in 2020 ?].
    Radermecker RP
    Rev Med Suisse; 2020 Aug; 16(703):1494-1497. PubMed ID: 32852170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Practical Guidance on Open Source and Commercial Automated Insulin Delivery Systems: A Guide for Healthcare Professionals Supporting People with Insulin-Requiring Diabetes.
    Lewis DM; Hussain S
    Diabetes Ther; 2022 Sep; 13(9):1683-1699. PubMed ID: 35913655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fully Automated Artificial Pancreas for Adults With Type 1 Diabetes Using Multiple Hormones: Exploratory Experiments.
    Majdpour D; Tsoukas MA; Yale JF; El Fathi A; Rutkowski J; Rene J; Garfield N; Legault L; Haidar A
    Can J Diabetes; 2021 Dec; 45(8):734-742. PubMed ID: 33888413
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advanced hybrid artificial pancreas system improves on unannounced meal response - In silico comparison to currently available system.
    Garcia-Tirado J; Lv D; Corbett JP; Colmegna P; Breton MD
    Comput Methods Programs Biomed; 2021 Nov; 211():106401. PubMed ID: 34560603
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The artificial pancreas: current status and future prospects in the management of diabetes.
    Peyser T; Dassau E; Breton M; Skyler JS
    Ann N Y Acad Sci; 2014 Apr; 1311():102-23. PubMed ID: 24725149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [From insulin pump and continuous glucose monitoring to the artificial pancreas].
    Apablaza P; Soto N; Codner E
    Rev Med Chil; 2017 May; 145(5):630-640. PubMed ID: 28898340
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Performance of an Automated Insulin Delivery System: Results of Early Phase Feasibility Studies.
    Christiansen M; Bartee A; Lalonde A; Jones RE; Katz M; Wolpert H; Brazg R
    Diabetes Technol Ther; 2021 Mar; 23(3):187-194. PubMed ID: 32940537
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.